We recently reported that both genetic and pharmacological VPS34 inhibition leads to increased effector immune cell infiltration and synergizes with PD‐1/PD‐L1 blockade therapy in murine melanoma and colorectal cancer (CRC) models [18]. Here, PDCD1 is linked to melanoma.